{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:01:21Z","timestamp":1775228481355,"version":"3.50.1"},"reference-count":0,"publisher":"Therapeutic Guidelines Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aust Prescr"],"published-print":{"date-parts":[[2016,4,1]]},"DOI":"10.18773\/austprescr.2016.010","type":"journal-article","created":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T05:46:30Z","timestamp":1452836790000},"page":"60-62","source":"Crossref","is-referenced-by-count":0,"title":["New drugs: Idelalisib"],"prefix":"10.18773","volume":"39","member":"39051","published-online":{"date-parts":[[2015,11,19]]},"container-title":["Australian Prescriber"],"original-title":[],"link":[{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/idelalisib-for-chronic-lymphocytic-leukaemia-and-follicular-lymphoma.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:16:55Z","timestamp":1775225815000},"score":1,"resource":{"primary":{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/idelalisib-for-chronic-lymphocytic-leukaemia-and-follicular-lymphoma.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,19]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,4,1]]},"published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.18773\/austprescr.2016.010","relation":{},"ISSN":["0312-8008","1839-3942"],"issn-type":[{"value":"0312-8008","type":"print"},{"value":"1839-3942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,19]]}}}